BARCELONA, Spain and CAMBRIDGE, Mass., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced today that Dr. Carlos Buesa, Oryzon’s Chief Executive Officer, will attend the 34th Annual J.P. Morgan Healthcare Conference on January 11–15, 2016 at the Westin St. Francis in San Francisco to discuss with industry leaders the potential of epigenetics in devastating diseases.
The company will also participate at the Biotech Showcase 2016 event where it will present the latest advances of its Epigenetic programs with special focus on its Alzheimer’s disease program ORY-2001. The presentation will be held in Room Mission I on Track B at the Parc55 Wyndham Union Square Hotel on Wednesday, January 13 at 2:00 PM PST.
The J.P. Morgan Healthcare Conference brings together industry leaders, financial sponsors and investors to explore innovation and market trends in the pharmaceutical industry. Every January San Francisco attracts additional parallel conferences and multilateral activities between all actors in the industry in a week that is widely viewed as setting the tone for the coming year. An example is the Biotech Showcase™ conference, one of the largest annual international healthcare conferences where Oryzon traditionally starts every year its calendar of public presentations.
Epigenetics is one of the most innovative areas in the industry and Oryzon will have the opportunity to discuss the prospects of its clinical programs with industry leaders and investors for the first time as a public company. “We are very excited to be attending the J.P. Morgan Conference as well as presenting at the 8th Annual Biotech Showcase. These events attract industry experts as well as the financial community. We look forward to the opportunity to highlight Oryzon’s accomplishments and development plans for the upcoming year,” commented Dr. Buesa.
Biotech Showcase™ is an investor and networking conference dedicated to providing an excellent opportunity to private and public biotechnology and life sciences companies to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare conferences. The event attracts industry leaders, innovators, company executives, investors, sector analysts and bankers.
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015), is a clinical stage biopharmaceutical company considered the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with ROCHE. Oryzon’s LSD1 program is currently covered by 19 patent families and has rendered one compound in clinical trials and another one is anticipated to enter clinical trials in early 2016. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.
This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates” and similar expressions.
Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public.
Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A, have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
US Contact: The Ruth Group Lee Roth/Tram Bui (646) 536-7012/7035 email@example.com firstname.lastname@example.org Spain: ATREVIA Ana Melgar/Patricia Cobo +34 91 564 07 25 email@example.com firstname.lastname@example.org The Company: Ms. Anna K Baran IR Director +44 (0) 752 1083 006 email@example.com